CMPS:US
$4.30
10.825%
COMPASS Pathways PlcNews & Events
Last updated: Jul 20, 2025, 2:04 PM ET
Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
Business Wire JUL 10, 2025 4:00 PM EDTCompass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient ac...READ ARTICLEGlobal Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
GlobeNewswire JUL 1, 2025 9:50 AM EDTPALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - ...READ ARTICLECompass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Business Wire JUN 23, 2025 6:30 AM EDTA single administration of COMP360 demonstrated a highly statistically significant and clinically...READ ARTICLECompass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
Business Wire MAY 14, 2025 6:30 AM EDTCompass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient ac...READ ARTICLECompass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
Business Wire MAY 8, 2025 6:30 AM EDTHighlights: 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resi...READ ARTICLECompass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
Business Wire APR 29, 2025 6:30 AM EDTCompass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient ac...READ ARTICLECompass Pathways to Announce First Quarter Financial Results on May 8, 2025
Business Wire APR 28, 2025 6:30 AM EDTCompass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pat...READ ARTICLECompass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Business Wire APR 22, 2025 6:00 AM EDTHighlights: Participants received a single dose of either 25 mg of COMP360 or placebo O...READ ARTICLECompass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Business Wire MAR 26, 2025 6:30 AM EDTHighlights: Screening closed for all sites and final participants being scheduled for d...READ ARTICLECompass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
Business Wire MAR 18, 2025 6:30 AM EDTHighlights: 52-week observational follow-up study from Phase 2b reveals single 25 mg CO...READ ARTICLE